Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Department of Defense, Washington Headquarters Services, Directorate for Information Operations and Reports (0704-0188), 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302. Respondents should be aware that notwithstanding any other provision of law, no person shall be subject to any penalty for failing to comply with a collection of information if it does not display a currently valid OMB control number. PLEASE DO NOT RETURN YOUR FORM TO THE ABOVE ADDRESS. 5f. WORK UNIT NUMBER
REPORT DATE
PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES)University of Iowa College of Medicine
PERFORMING ORGANIZATION REPORT NUMBERIowa City, Iowa 52242
SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) 10. SPONSOR/MONITOR'S ACRONYM(S)U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012
SPONSOR/MONITOR'S REPORT NUMBER(S)
DISTRIBUTION / AVAILABILITY STATEMENTApproved for Public Release; Distribution Unlimited
SUPPLEMENTARY NOTES
ABSTRACTThe most significant finding of this research study during this period is the validation of resistance to fluid shear stress as a biomarker of prostate cancer cells. This initial finding has been published. Additional efforts have been undertaken to detect this biomarker in circulating tumor cells from blood samples from prostate cancer patients. This involves the development of methods to achieve this goal. Figure 2. We have applied this approach to an initial set of 3 prostate cancer patients in which a blood sample was taken 1d prior to prostatectomy and 1d post-operative. These initial findings are summarized in Figure 3. These findings are encouraging and suggest that CTCs are detectable by this method at the time of prostatectomy. In principle, our assay for FSS resistance could be applied at this time and this biomarker may indicate the degree to which these cells have the propensity to progress to metastasis. Additional findings are that very few cells detected are double-positive for EpCAM and N-Cadherin, and there is a possibility that CTC numbers increase from pre-operative to post-operative day 1, suggesting that surgical manipulation may increase CTC numbers in this setting. However, these findings are highly preliminary at this point. Additional studies are underway to confirm the identity of these cells as prostate CTC's by staining for PSA and/or PSMA.
SUBJECT TERMSSOW 1c. Accrue and analyze patient samples (Months 9-23) As noted above, 3 patients have been accrued in the validation portion of this proposal. Once we have established that the cells we are measuring ate bona-fide prostate cancer CTCs, we will ...